Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
8.0
4.5
Journals
Cancers
Special Issues
Advances in Bladder Preservation Approaches for Bladder Cancer (Volume II)
share announcement

Advances in Bladder Preservation Approaches for Bladder Cancer (Volume II)

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Epidemiology and Prevention".

Deadline for manuscript submissions: 28 February 2025 | Viewed by 2419

Special Issue Editors

Dr. Jay J. Liao

E-Mail Website
Guest Editor
University of Washington Medical Center, Fred Hutchinson Cancer Center, Seattle, WA, USA
Interests: genitourinary cancers; prostate cancer; bladder cancer; head and neck cancer; salivary gland cancer; particle radiotherapy; proton therapy; neutron therapy
Special Issues, Collections and Topics in MDPI journals
Dr. Todd A. Yezefski

E-Mail Website
Guest Editor
University of Washington School of Medicine, Seattle, WA, USA
Interests: prostate cancer; bladder cancer; penile cancer; testicular cancer

Special Issue Information

Dear Colleagues,

Bladder cancer is the 10th most common cancer worldwide. Surgical management with radical cystectomy and urinary diversion is the primary definitive treatment for most operable patients with muscle-invasive disease. Cystectomy is also a standard salvage therapy for patients with high-risk, non-muscle-invasive disease that is recurrent or persistent after conservative management and intravesical therapy. However, advanced age and medical comorbidities in this patient population often impact surgical candidacy. Many patients also decline cystectomy given the significant quality of life factors related to radical surgery and urinary diversion. Hence, there has been significant interest in non-surgical options for bladder preservation, either as a definitive treatment or to delay the need for cystectomy.

In this Special Issue, we will invite submissions including original research studies and contemporary reviews of current therapeutic strategies advancing the field of bladder preservation for bladder cancer. This may encompass updates on intravesical therapy, the emerging role of systemic therapy, including immunotherapy, and advances in radiotherapy and chemoradiation (trimodality therapy).

Dr. Jay J. Liao
Dr. Todd A. Yezefski
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • bladder cancer
  • bladder preservation
  • trimodality therapy
  • chemoradiation
  • immunotherapy
  • intravesical therapy
  • BCG refractory or unresponsive

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

11 pages, 2049 KiB  
Article
Muscle-Invasive Bladder Cancer in Non-Curative Patients: A Study on Survival and Palliative Care Needs
by Félix Guerrero-Ramos, Daniel Antonio González-Padilla, Santiago Pérez-Cadavid, Esther García-Rojo, Ángel Tejido-Sánchez, Mario Hernández-Arroyo, Carmen Gómez-Cañizo and Alfredo Rodríguez-Antolín
Cancers 2024, 16(19), 3330; https://doi.org/10.3390/cancers16193330 - 29 Sep 2024
Viewed by 983
Abstract
Objective: To assess the survival outcomes of patients diagnosed with muscle-invasive bladder cancer (MIBC) who are not candidates for curative treatment and to identify the factors influencing these outcomes. Methods: We conducted an analysis of patients diagnosed with MIBC who were either unable [...] Read more.
Objective: To assess the survival outcomes of patients diagnosed with muscle-invasive bladder cancer (MIBC) who are not candidates for curative treatment and to identify the factors influencing these outcomes. Methods: We conducted an analysis of patients diagnosed with MIBC who were either unable or unwilling to undergo curative therapy. We evaluated overall survival (OS) and cancer-specific survival (CSS) and examined their associations with various clinical variables. Additionally, we assessed emergency department visits and palliative procedures. Results: The study included 142 patients with a median age of 79.4 years and a Charlson Comorbidity Index of 9.8. At diagnosis, 59.2% of the patients had localized disease, 23.2% had metastatic disease, and 49.3% presented with hydronephrosis. Curative treatment was excluded due to comorbidities in 40.1% of cases and advanced disease stage in 36.6%. The 1-year and 2-year OS rates were 42.8% and 23.6%, respectively, with a median survival of 10.6 months. The 1-year and 2-year CSS rates were 49.6% and 30.2%, respectively, with a median survival of 11.9 months. Worse survival outcomes were associated with advanced disease stage and the presence of hydronephrosis. Patients excluded from curative treatment solely due to age had a relatively better prognosis. On average, patients visited the emergency department three times: 19% underwent palliative transurethral resection of the bladder tumor, 14.8% received radiotherapy to control hematuria, and nephrostomy tubes were placed in 26.1% of cases. Conclusions: Patients with MIBC who are unable or unwilling to undergo curative treatment have a median overall survival of less than one year, with worse outcomes observed in those with advanced disease stage and hydronephrosis. Full article
(This article belongs to the Special Issue Advances in Bladder Preservation Approaches for Bladder Cancer (Volume II))
►▼ Show Figures

Figure 1

12 pages, 1195 KiB  
Article
Sequential Endoluminal Gemcitabine and Cabazitaxel with Intravenous Pembrolizumab as a Bladder-Preserving Strategy for Docetaxel-Unresponsive Non-Muscle Invasive Urothelial Carcinoma Following Transurethral Resection of Bladder Tumor
by Ian M. McElree, Vignesh T. Packiam, Ryan L. Steinberg, Helen Y. Hougen, Sarah L. Mott, Mohamad Abou Chakra, Yousef Zakharia and Michael A. O’Donnell
Cancers 2024, 16(14), 2561; https://doi.org/10.3390/cancers16142561 - 17 Jul 2024
Viewed by 1024
Abstract
Growing evidence suggests that many patients with high-risk non-muscle invasive urothelial carcinoma (NMIUC) can undergo bladder-sparing management with salvage intravesical therapies. However, inherent or developed disease resistance, particularly after multiple lines of prior salvage therapy, implores the continued pursuit of new treatment combinations. [...] Read more.
Growing evidence suggests that many patients with high-risk non-muscle invasive urothelial carcinoma (NMIUC) can undergo bladder-sparing management with salvage intravesical therapies. However, inherent or developed disease resistance, particularly after multiple lines of prior salvage therapy, implores the continued pursuit of new treatment combinations. Herein, we describe the outcomes of 26 patients (31 treated units; 24 lower tract, 7 upper tract) with high-risk NMIUC treated with sequential intravesical gemcitabine and cabazitaxel with concomitant intravenous pembrolizumab (GCP) at the University of Iowa from August 2020 to February 2023. Median (IQR) follow-up was 30 (IQR: 17–35) months. Treated units had a history of high-risk NMIUC with a median of four prior endoluminal inductions. Overall, 87% of units presented with CIS or positive urine cytology. The 1- and 2-year recurrence-free survival was 77% (CI: 58–88%) and 52% (CI: 30–70%), respectively. The 2-year progression-free and cancer-specific survival was 70% (CI: 44–85%) and 96% (CI: 75–99%), respectively. In total, 22/26 (85%) patients reported any adverse event and 5/26 (19%) reported a grade ≥3 adverse event; however, all patients tolerated a full induction course. These results suggest that GCP is an effective and tolerable treatment option for patients with recurrent high-risk NMIUC. Full article
(This article belongs to the Special Issue Advances in Bladder Preservation Approaches for Bladder Cancer (Volume II))
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop